Literature DB >> 226672

Selective inhibitor of platelet cyclic adenosine monophosphate phosphodiesterase, cilostamide, inhibits platelet aggregation.

H Hidaka, H Hayashi, H Kohri, Y Kimura, T Hosokawa, T Igawa, Y Saitoh.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 226672

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


× No keyword cloud information.
  17 in total

Review 1.  Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments.

Authors:  Thérèse Keravis; Claire Lugnier
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

2.  L-arginine induces relaxation of rat aorta possibly through non-endothelial nitric oxide formation.

Authors:  H Moritoki; H Ueda; T Yamamoto; T Hisayama; S Takeuchi
Journal:  Br J Pharmacol       Date:  1991-04       Impact factor: 8.739

3.  Open-Label Phase I Clinical Study to Assess the Safety and Efficacy of Cilostazol in Patients Undergoing Internal Carotid Artery Stent Placement.

Authors:  Ameer E Hassan; Haralabos Zacharatos; Mikayel Grigoryan; Wondwossen G Tekle; Amir Khan; Farhan Siddiq; Gustavo J Rodriguez; Ramachandra Tummala; Bharathi Jagadeesan; M Fareed K Suri; Adnan I Qureshi
Journal:  Interv Neurol       Date:  2016-12-08

4.  Immunological identification of the major platelet low-Km cAMP phosphodiesterase: probable target for anti-thrombotic agents.

Authors:  C H Macphee; S A Harrison; J A Beavo
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

Review 5.  Can Cyclic Nucleotide Phosphodiesterase Inhibitors Be Drugs for Parkinson's Disease?

Authors:  Dominic Ngima Nthenge-Ngumbau; Kochupurackal P Mohanakumar
Journal:  Mol Neurobiol       Date:  2017-01-06       Impact factor: 5.590

6.  Suppression of arterial intimal hyperplasia by cilostamide, a cyclic nucleotide phosphodiesterase 3 inhibitor, in a rat balloon double-injury model.

Authors:  Y Inoue; K Toga; T Sudo; K Tachibana; S Tochizawa; Y Kimura; Y Yoshida; H Hidaka
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

7.  An unsuspected property of natriuretic peptides: promotion of calcium-dependent catecholamine release via protein kinase G-mediated phosphodiesterase type 3 inhibition.

Authors:  Noel Yan-Ki Chan; Nahid Seyedi; Kenichi Takano; Roberto Levi
Journal:  Circulation       Date:  2011-12-09       Impact factor: 29.690

8.  Characterization of novel phosphodiesterases in the bovine ovarian follicle.

Authors:  Maxime Sasseville; Firas K Albuz; Nancy Côté; Christine Guillemette; Robert B Gilchrist; François J Richard
Journal:  Biol Reprod       Date:  2009-04-08       Impact factor: 4.285

9.  Natriuretic peptide-induced catecholamine release from cardiac sympathetic neurons: inhibition by histamine H3 and H4 receptor activation.

Authors:  Noel Yan-Ki Chan; Pablo A Robador; Roberto Levi
Journal:  J Pharmacol Exp Ther       Date:  2012-08-24       Impact factor: 4.030

10.  Inhibition of aggregation and secretion of human platelets by quercetin and other flavonoids: structure-activity relationships.

Authors:  A Beretz; J P Cazenave; R Anton
Journal:  Agents Actions       Date:  1982-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.